Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday ... selective PI3K-inhibitor program. "We enter 2025 with tremendous momentum and ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue increase Eli Lilly & Co. said its ... PI3K inhibitor program. "We enter 2025 with tremendous momentum and ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...